AbbVie Sues Amgen to Fend Off Copy of Blockbuster Humira

  • Drugmaker claims Amgen’s proposed copy infringes 10 patents
  • AbbVie says it has 51 other patents for arthritis medicine

Biotechnology drugmaker AbbVie Inc. filed a lawsuit seeking to block Amgen Inc. from selling a copy of the arthritis medicine Humira, its top seller.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.